Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Quantifying Misstatement in Current Year Financial Statements, Amount

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Quantifying Misstatement in Current Year Financial Statements, Amount

EMERGENT BIOSOLUTIONS INC. (EBS) reported Quantifying Misstatement in Current Year Financial Statements, Amount of $2.60 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-08-06.

Discontinued › Notes

us-gaap:QuantifyingMisstatementInCurrentYearFinancialStatementsAmount · last filed 2013-11-08

  • 2013-06-30: Quantifying Misstatement in Current Year Financial Statements, Amount 6 month $2.60M.
  • 2012-09-30: Quantifying Misstatement in Current Year Financial Statements, Amount 9 month $3.00M.
Period endQuantifying Misstatement in Current Year Financial Statements, Amount 6 monthQuantifying Misstatement in Current Year Financial Statements, Amount 9 month
2013-06-30$2.60M
10-Q · filed 2013-08-06
2012-09-30$3.00M
10-Q · filed 2013-11-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45